Uncategorized

First FDA ODAC meeting without Pazdur highlights conceptual challenges with trial

The advisory committee meeting—the FDA’s first drug-related adcomm in nine months—could have been a “more conceptual discussion” about the design of AstraZeneca’s Phase 3 trial of camizestrant in HER2-negative advanced breast cancer, former cancer regulator Harpreet Singh told BioSpace.

First FDA ODAC meeting without Pazdur highlights conceptual challenges with trial Read More »

Scroll to Top